Home > News > Majority Investment Made in New Nanotech Subsidiary
April 22nd, 2004
Majority Investment Made in New Nanotech Subsidiary
Arrowhead Research Corporation, an emerging company in the field of nanotechnology, announced today that it has agreed to take a majority position in Insert Therapeutics, Inc., a Pasadena-based company focused on designing, developing and commercializing delivery-enhanced therapeutics using its patented class of polymers.
Nanometrics Announces Participation in 5th Annual CEO Investor Summit: Accredited Investor and Publishing Research Analyst Event to be Held Concurrently With SEMICON West and Intersolar 2013 in San Francisco June 19th, 2013
Dr. Ben J. Lipps designated as Chairman of the Management Board and Chief Executive Officer of Nanostart-holding MagForce AG June 17th, 2013
Harris & Harris Group Notes Carl Zeiss' Planned Acquisition of Xradia June 13th, 2013
Long Island Capital Alliance Announces Participants for Biotech Technology Transfer Capital Forum: Event to Be Held on June 14 in Collaboration With Cold Spring Harbor Laboratory June 8th, 2013